{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:26:04Z","timestamp":1747826764233,"version":"3.40.5"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union Horizon 2020 research and Innosuisse \u2013 Swiss Innovation Agency","award":["E!113321_CHAPERONE"],"award-info":[{"award-number":["E!113321_CHAPERONE"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal disease caused by lowered activity of the enzyme alpha-L-iduronidase (IDUA). Current therapeutic options show limited efficacy and do not treat some important aspects of the disease. Therefore, it may be advantageous to identify strategies that could improve the efficacy of existing treatments. Pharmacological chaperones are small molecules that protect proteins from degradation, and their use in combination with enzyme replacement therapy (ERT) has been proposed as an alternative therapeutic strategy. Using the SEE-Tx<jats:sup>\u00ae<\/jats:sup> proprietary computational drug discovery platform, a new allosteric ligand binding cavity in IDUA was identified distal from the active site. Virtual high-throughput screening of approximately 5 million compounds using the SEE-Tx<jats:sup>\u00ae<\/jats:sup> docking platform identified a subset of small molecules that bound to the druggable cavity and functioned as novel allosteric chaperones of IDUA. Experimental validation by differential scanning fluorimetry showed an overall hit rate of 11.4%. Biophysical studies showed that one exemplary hit molecule GT-01803 bound to (Kd = 22 \u03bcM) and stabilized recombinant human IDUA (rhIDUA) in a dose-dependent manner. Co-administration of rhIDUA and GT-01803 increased IDUA activity in patient-derived fibroblasts. Preliminary <jats:italic>in vivo<\/jats:italic> studies have shown that GT-01803 improved the pharmacokinetic (PK) profile of rhIDUA, increasing plasma levels in a dose-dependent manner. Furthermore, GT-01803 also increased IDUA enzymatic activity in bone marrow tissue, which benefits least from standard ERT. Oral bioavailability of GT-01803 was found to be good (50%). Overall, the discovery and validation of a novel allosteric chaperone for rhIDUA presents a promising strategy to enhance the efficacy of existing treatments for MPS I. The compound\u2019s ability to increase rhIDUA activity in patient-derived fibroblasts and its good oral bioavailability underscore its potential as a potent adjunct to ERT, particularly for addressing aspects of the disease less responsive to standard treatment.<\/jats:p>","DOI":"10.1371\/journal.pone.0303789","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:30:30Z","timestamp":1716226230000},"page":"e0303789","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Discovery of allosteric regulators with clinical potential to stabilize alpha-L-iduronidase in mucopolysaccharidosis type I"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2239-6670","authenticated-orcid":true,"given":"Elena","family":"Cubero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-1347","authenticated-orcid":true,"given":"Xavier","family":"Barril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Trapero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manolo","family":"Bellotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Maj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz Calvo-Flores","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"P\u00e9rez-Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Garcia-Collazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"10","key":"pone.0303789.ref001","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","article-title":"The natural history of MPS I: global perspectives from the MPS I Registry","volume":"16","author":"M Beck","year":"2014","journal-title":"Genet Med"},{"issue":"4","key":"pone.0303789.ref002","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment","volume":"33","author":"R Giugliani","year":"2010","journal-title":"Genet Mol Biol"},{"issue":"8","key":"pone.0303789.ref003","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081838","article-title":"Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology","volume":"9","author":"CS Hampe","year":"2020","journal-title":"Cells"},{"issue":"2","key":"pone.0303789.ref004","article-title":"Epidemiology of Mucopolysaccharidoses Update","volume":"11","author":"B \u00c7elik","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"pone.0303789.ref005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"MH de Ru","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 2","key":"pone.0303789.ref006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"D Concolino","year":"2018","journal-title":"Ital J Pediatr"},{"issue":"6","key":"pone.0303789.ref007","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme (\u00ae)) for treating mucopolysaccharidosis type I","volume":"6","author":"E Jameson","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0303789.ref008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Y Xue","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"3","key":"pone.0303789.ref009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15171\/bi.2018.17","article-title":"Enzyme replacement therapies: what is the best option?","volume":"8","author":"A Safary","year":"2018","journal-title":"Bioimpacts"},{"issue":"10","key":"pone.0303789.ref010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","article-title":"Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments","volume":"79","author":"K Sawamoto","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"pone.0303789.ref011","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"DP Germain","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0303789.ref012","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3390\/ijms23031887","article-title":"Chaperone Therapy in Fabry Disease","volume":"23","author":"F Weidemann","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"pone.0303789.ref013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"A Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"48","key":"pone.0303789.ref014","doi-asserted-by":"crossref","first-page":"50257","DOI":"10.1074\/jbc.M405738200","article-title":"Antigen stability controls antigen presentation","volume":"279","author":"R Thai","year":"2004","journal-title":"J Biol Chem"},{"issue":"7","key":"pone.0303789.ref015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders","volume":"23","author":"G Parenti","year":"2015","journal-title":"Mol Ther"},{"issue":"6","key":"pone.0303789.ref016","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"C Porto","year":"2009","journal-title":"Mol Ther"},{"issue":"7","key":"pone.0303789.ref017","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"R Khanna","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"pone.0303789.ref018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"C Porto","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"pone.0303789.ref019","unstructured":"Barril X, Cubero E, Delgado A, et al. Allosteric regulators improving biodistribution of recombinant laronidase in Mucopolysaccharidosis type 1 (MPS1). ePoster presented at the virtual 17th Annual WORLDSymposium\u2122 2021."},{"issue":"36","key":"pone.0303789.ref020","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1073\/pnas.1306939110","article-title":"Human \u03b1-L-iduronidase uses its own N-glycan as a substrate-binding and catalytic module","volume":"110","author":"N Maita","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pone.0303789.ref021","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1021\/jm801385d","article-title":"Binding site detection and druggability index from first principles","volume":"52","author":"J Seco","year":"2009","journal-title":"J Med Chem"},{"issue":"20","key":"pone.0303789.ref022","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1021\/jm5010418","article-title":"Molecular Simulations with Solvent Competition Quantify Water Displaceability and Provide Accurate Interaction Maps of Protein Binding Sites","volume":"57","author":"D Alvarez-Garcia","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"pone.0303789.ref023","first-page":"62","article-title":"Extracting Atomic Contributions to Binding Free Energy Using Molecular Dynamics Simulations with Mixed Solvents (MDmix)","volume":"19","author":"D Alvarez-Garcia","year":"2022","journal-title":"Curr Drug Discov Technol"},{"key":"pone.0303789.ref024","unstructured":"Barril-Alonso X, Alvarez-Garcia D, Schmistke P. Method of binding site and binding energy determination by mixed explicit solvent simulations. Patent (WO 2013092922 A2) 2012. [https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2013092922] Accessed 2022 October."},{"issue":"4","key":"pone.0303789.ref025","doi-asserted-by":"crossref","first-page":"e1003571","DOI":"10.1371\/journal.pcbi.1003571","article-title":"rDock: A Fast, Versatile and Open Source Program for Docking Ligands to Proteins and Nucleic Acids","volume":"10","author":"S Ruiz-Carmona","year":"2014","journal-title":"PLOS Computational Biology"},{"issue":"9","key":"pone.0303789.ref026","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"FH Niesen","year":"2007","journal-title":"Nature Protocols"},{"key":"pone.0303789.ref027","unstructured":"Garc\u00eda-Collazo AM, Cubero-Jord\u00e0 E, Barril-Alonso X, et al. Combination therapy for treating MPS1. Patent (WO 202021156774) 2021. [https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2021156774] Accessed 2022 October."},{"issue":"6","key":"pone.0303789.ref028","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bab.52","article-title":"Biochemical characterization of fluorescent-labeled recombinant human alpha-L-iduronidase in vitro","volume":"58","author":"BL Tippin","year":"2011","journal-title":"Biotechnol Appl Biochem"},{"issue":"2","key":"pone.0303789.ref029","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/ci600426e","article-title":"Evaluating virtual screening methods: good and bad metrics for the \"early recognition\" problem","volume":"47","author":"JF Truchon","year":"2007","journal-title":"J Chem Inf Model"},{"issue":"17","key":"pone.0303789.ref030","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.1021\/jm301916b","article-title":"Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis","volume":"56","author":"T Zhu","year":"2013","journal-title":"J Med Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:30:56Z","timestamp":1716226256000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303789"}},"subtitle":[],"editor":[{"given":"Nirakar","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0303789","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}